Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Arvinas, Inc. - Common Stock (NQ:ARVN)

7.210 +0.120 (+1.69%)
Delayed Quote Updated: 10:51 AM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Arvinas, Inc. - Common Stock

< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
News headline image
Where Arvinas Stands With Analysts ↗
 
Via Benzinga
News headline image
3 Small-Cap Biopharma Stocks that Could See Big Growth in 2023
Health care stocks are trying to make a comeback and these three small-cap biopharma companies are leading the charge in some ways. 
Via MarketBeat
Where Arvinas Stands With Analysts ↗
 
Via Benzinga
News headline image
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
News headline image
Looking Into Arvinas's Return On Invested Capital ↗
 
Via Benzinga
News headline image
Analyst Ratings for Arvinas ↗
 
Via Benzinga
Where Arvinas Stands With Analysts ↗
 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Monday ↗
Companies That Fell Through 52-Week Lows Monday During Monday's morning trading, 14 companies set new 52-week lows. 
Via Benzinga
News headline image
Arvinas to Present at 41st Annual J.P. Morgan Healthcare Conference
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Changes to its Board of Directors
From Arvinas Inc.
Via GlobeNewswire
News headline image
Baidu To $180? Plus This Analyst Cuts PT On MacroGenics By 56% ↗
Mizuho cut the price target on Baidu, Inc. (NASDAQ: BIDU) from $200 to $180. Mizuho analyst James Lee maintained the stock with a Buy rating. Baidu shares rose 2.5% to trade at $97.49 on Wednesday. 
Via Benzinga
News headline image
Where Arvinas Stands With Analysts ↗
Within the last quarter, Arvinas (NASDAQ:ARVN) has observed the following analyst ratings: 
Via Benzinga
News headline image
Expert Ratings for Arvinas ↗
Within the last quarter, Arvinas (NASDAQ:ARVN) has observed the following analyst ratings: 
Via Benzinga
News headline image
Burlington Stores To Surge Over 21%? Plus Wedbush Slashes PT On Jack In The Box ↗
Barclays raised the price target on Burlington Stores, Inc. (NYSE: BURL) from $164 to $230. Barclays analyst Adrienne Yih maintained an Overweight rating on the stock. Burlington shares fell 0.1% to... 
Via Benzinga
News headline image
Abercrombie & Fitch To Rally 21%? Plus This Analyst Predicts $237 For Autodesk ↗
  Telsey Advisory Group raised the price target on Abercrombie & Fitch Co. (NYSE: ANF) from $25 to $27. Abercrombie & Fitch shares fell 1.2% to $22.34 in pre-market trading. 
Via Benzinga
News headline image
Arvinas's ARV-471 Achieves Clinical Benefit Rate Of 38% In Breast Cancer Setting ↗
 
Via Benzinga
News headline image
Arvinas Announces ARV-471 Achieves a Clinical Benefit Rate of 38% in Evaluable Patients and Continues to Show a Favorable Tolerability Profile in its Phase 2 Expansion Trial (VERITAC)
From Arvinas Inc.
Via GlobeNewswire
News headline image
Carvana, Crocs And Other Big Losers From Monday ↗
U.S. stocks closed lower on Monday, with the Nasdaq dropping more than 100 points. Here is the list of some big stocks recording losses in the previous session. 
Via Benzinga
News headline image
Why Drive Shack Shares Jumped Over 23%; Here Are 76 Biggest Movers From Yesterday ↗
Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares climbed 104.5% to close at $35.59 on Monday after Merck announced it would acquire the company for $36 per share in cash. 
Via Benzinga
News headline image
Why TuanChe Shares Are Trading Lower By 76%? Here Are 48 Stocks Moving In Monday's Mid-Day Session ↗
Gainers Imago BioSciences, Inc. (NASDAQ: IMGO) shares jumped 104% to $35.50 after Merck announced it would acquire the company for $36 per share in cash. 
Via Benzinga
News headline image
Arvinas Reports Third Quarter 2022 Financial Results and Provides Corporate Update
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas to Present at Upcoming Conferences
From Arvinas Inc.
Via GlobeNewswire
News headline image
Arvinas Announces Winner of the 2022 Arvinas Early Career Researcher Award
Katherine Donovan, Ph.D. of the Dana-Farber Cancer Institute has been awarded a $25,000 monetary prize recognizing her innovation in the field of targeted protein degradation 
From Arvinas Inc.
Via GlobeNewswire
News headline image
Wingstop, Harley-Davidson, Rollins And Some Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded mixed, with the Dow Jones gaining more than 200 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Why New Oriental Education Shares Jumped Over 28%; Here Are 68 Biggest Movers From Yesterday ↗
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares climbed 180.2% to close at $4.82 on Wednesday after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the... 
Via Benzinga
News headline image
Arvinas Appoints Paul McInulty as Senior Vice President, Regulatory Affairs
From Arvinas Inc.
Via GlobeNewswire
News headline image
Why Seagate Shares Are Trading Lower By More Than 7%? Here Are 49 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers ESSA Pharma Inc. (NASDAQ: EPIX) shares surged 59.3% to $2.7417 after the company highlighted updates results from the Phase 1/2 study of EPI-7386 with Enzalutamide At the 29th Annual Prostate... 
Via Benzinga
News headline image
Arvinas Gives Back to Local Greater New Haven Community
From Arvinas Inc.
Via GlobeNewswire
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022 ↗
Upgrades 
Via Benzinga
News headline image
Arvinas's Return on Invested Capital Insights ↗
According to Benzinga Pro data, Arvinas (NASDAQ:ARVN) reported Q2 sales of $31.30 million. Earnings fell to a loss of $70.00 million, resulting in a 10.41% decrease from last quarter. 
Via Benzinga
< Previous 1 2
...
4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.